期刊
JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY
卷 28, 期 5, 页码 406-410出版社
MARY ANN LIEBERT, INC
DOI: 10.1089/jamp.2015.1221
关键词
aerosols; interstitial lung disease; nebulizers; pulmonary function test
Parenteral IFN- was unsuccessful as a treatment for pulmonary fibrosis. Inhaled IFN- targeted to the lungs may be more effective. Our patient, a 56-year-old male with biopsy proven usual interstitial pneumonia (UIP) and declining pulmonary function tests (PFTs) was initially diagnosed with idiopathic pulmonary fibrosis (IPF). He enrolled in a 2-year research protocol and was treated with inhaled IFN- (100g, Actimmune, Horizon Pharma, Deerfield, IL) 3 times per week. After completion of the protocol, he was able to secure the drug and continued therapy for a total of 7 years. He felt better, returning to work. His only complaint was transient cough during inhalation. PFTs improved (e.g., DLCO, 58% at baseline, 81% at 2 years, 69% currently). Clinical monitoring showed preserved exercise tolerance and stable CT scans. He was ultimately diagnosed (year 5) with scleroderma-like connective tissue disease after he developed sclerodactyly and a positive antinuclear antibody. Inhaled IFN- was well tolerated for 7 years and may stabilize fibrotic lung disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据